Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Johnson & JohnsonNYSE: JNJ

EPS (Diluted) · Q3 FY2026 · quarter ended Sep 2026

EPS (Diluted) declines year over year

Q3 FY2026 EPS (Diluted) of $0.09 fell 96.0% year over year, behind the -36.3% change in trailing-twelve-month EPS (Diluted). Sequentially, it fell 96.2% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.

Context

  • EPS (Diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 11 analysts of $11.11 (+0.8%) for the fiscal year ending Dec 2026, a slowdown from the +90.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$0.09-96.2% QoQ
Last fiscal yearDec 2025
$11.03+90.5% YoY
LTMSep 2026
$6.6-36.3% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-96.0%+38.7%+134.6 pp
1 year+90.5%+0.8%-89.7 pp
3-year CAGR+17.9%+8.1%-9.8 pp
5-year CAGR+9.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
11.03 USD
Year-over-year change
+90.5%
4-year CAGR
+9.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -36.3% is the 7th highest of 11, against a peer median of +6.5%.
  • Over three fiscal years its annual growth of +17.9% compares with a peer median of +5.4%.
JNJ Competitors
EPS (Diluted) for JNJ and competitors
Company Period LTM YoY 3-year CAGR
AMGNAmgen Inc.LTM Jun 2026$16.09 USD+31.6%+5.5%
AZNAstraZeneca PLCLTM Sep 2026$7.01 USD+16.4%+45.8%
NVSNovartis AGLTM Jun 2026$6.63 USD-3.4%+31.4%
JNJJohnson & JohnsonLTM Sep 2026$6.6 USD-36.3%+17.9%
ABBVAbbVie Inc.LTM Sep 2026$5.83 USD+338.0%-29.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$4.54 USD+83.4%+5.4%
GSKGSK plcLTM Jun 2026£2.37 GBP+43.5%-27.6%
MRKMerck & Co., Inc.LTM Jun 2026$1.25 USD-80.7%+8.4%
PFEPfizer Inc.LTM Jun 2026$0.76 USD-59.9%-37.1%
SNYSanofiLTM Jun 2026€0.49 EUR-87.2%+0.2%
GILDGilead Sciences, Inc.LTM Jun 2026-$2.67 USD-153.2%+23.0%
Peer median (excluding JNJ) —+6.5%+5.4%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.74B79.99B85.16B88.82B94.19B
Cost of Revenue23.4B24.6B26.55B27.47B30.26B
Gross Profit55.34B55.39B58.61B61.35B63.94B
Gross Margin70.3%69.3%68.8%69.1%67.9%
Research & Development14.28B14.14B15.09B17.23B14.67B
Selling, General & Admin20.12B20.25B20.11B21.97B23.68B
Operating Expenses34.4B34.38B35.2B39.2B38.34B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
EBITDA26.75B26.61B23.32B24.78B41.06B
EBITDA Margin34.0%33.3%27.4%27.9%43.6%
Operating Income20.94B21.01B23.41B22.15B25.6B
Operating Margin26.6%26.3%27.5%24.9%27.2%
Interest Income53M490M1.26B1.33B1.06B
Interest Expense183M276M772M755M971M
Other Income / Expenses(1.77B)(1.65B)(8.35B)(5.46B)6.99B
Income Before Tax19.18B19.36B15.06B16.69B32.58B
Pre-Tax Margin24.4%24.2%17.7%18.8%34.6%
Income Tax Expense1.38B2.99B1.74B2.62B5.78B
Net Income20.88B17.94B35.15B14.07B26.8B
Net Margin26.5%22.4%41.3%15.8%28.5%
EPS (Basic)7.936.8313.885.8411.03
EPS (Diluted)7.816.7313.725.7911.03
Weighted Avg Shares2.63B2.61B2.53B2.41B2.43B
Weighted Avg Shares (Diluted)2.67B2.66B2.56B2.43B2.43B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.